| Targeting nuclear factor-kappa B to overcome resistance to chemotherapy P Godwin, AM Baird, S Heavey, MP Barr, KJ O’Byrne, K Gately Frontiers in oncology 3, 120, 2013 | 278 | 2013 |
| Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC S Heavey, KJ O’Byrne, K Gately Cancer treatment reviews 40 (3), 445-456, 2014 | 158 | 2014 |
| PIM kinase inhibition: Co-targeted therapeutic approaches in prostate cancer S Luszczak, C Kumar, VK Sathyadevan, BS Simpson, KA Gately, ... Signal transduction and targeted therapy 5 (1), 7, 2020 | 54 | 2020 |
| VERDICT MRI for prostate cancer: intracellular volume fraction versus apparent diffusion coefficient EW Johnston, E Bonet-Carne, U Ferizi, B Yvernault, H Pye, D Patel, ... Radiology 291 (2), 391-397, 2019 | 48 | 2019 |
| INNOVATE: A prospective cohort study combining serum and urinary biomarkers with novel diffusion-weighted magnetic resonance imaging for the prediction and characterization of … E Johnston, H Pye, E Bonet-Carne, E Panagiotaki, D Patel, M Galazi, ... BMC cancer 16 (1), 1-11, 2016 | 44 | 2016 |
| MicroRNA-17 is downregulated in esophageal adenocarcinoma cancer stem-like cells and promotes a radioresistant phenotype N Lynam-Lennon, S Heavey, G Sommerville, BAS Bibby, B Ffrench, ... Oncotarget 8 (7), 11400, 2017 | 43 | 2017 |
| Apparatus for histological validation of in vivo and ex vivo magnetic resonance imaging of the human prostate RM Bourne, C Bailey, EW Johnston, H Pye, S Heavey, H Whitaker, B Siow, ... Frontiers in oncology, 47, 2017 | 35 | 2017 |
| Strategic targeting of the PI3K–NFκB axis in cisplatin-resistant NSCLC S Heavey, P Godwin, AM Baird, MP Barr, K Umezawa, S Cuffe, SP Finn, ... Cancer biology & therapy 15 (10), 1367-1377, 2014 | 33 | 2014 |
| The oncogene metadherin interacts with the known splicing proteins YTHDC1, Sam68 and T-STAR and plays a novel role in alternative mRNA splicing HJ Luxton, BS Simpson, IG Mills, NR Brindle, Z Ahmed, V Stavrinides, ... Cancers 11 (9), 1233, 2019 | 26 | 2019 |
| In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC S Heavey, S Cuffe, S Finn, V Young, R Ryan, S Nicholson, N Leonard, ... Oncotarget 7 (48), 79526, 2016 | 24 | 2016 |
| Targeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLC SL Ryan, S Beard, MP Barr, K Umezawa, S Heavey, P Godwin, SG Gray, ... Lung Cancer 135, 217-227, 2019 | 22 | 2019 |
| An optimised saliva collection method to produce high-yield, high-quality RNA for translational research R Sullivan, S Heavey, DG Graham, R Wellman, S Khan, S Thrumurthy, ... PLoS One 15 (3), e0229791, 2020 | 19 | 2020 |
| Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer T Malone, L Schäfer, N Simon, S Heavey, S Cuffe, S Finn, G Moore, ... Pharmacology & Therapeutics 207, 107454, 2020 | 19 | 2020 |
| VERDICT MRI validation in fresh and fixed prostate specimens using patient‐specific moulds for histological and MR alignment C Bailey, RM Bourne, B Siow, EW Johnston, M Brizmohun Appayya, ... NMR in Biomedicine 32 (5), e4073, 2019 | 19 | 2019 |
| Cellular senescence as a possible link between prostate diseases of the ageing male G Fiard, V Stavrinides, ES Chambers, S Heavey, A Freeman, R Ball, ... Nature Reviews Urology 18 (10), 597-610, 2021 | 15 | 2021 |
| Evaluation of PSA and PSA density in a multiparametric magnetic resonance Imaging-Directed diagnostic pathway for suspected prostate cancer: the INNOVATE trial H Pye, S Singh, JM Norris, LM Carmona Echeverria, V Stavrinides, A Grey, ... Cancers 13 (8), 1985, 2021 | 12 | 2021 |
| Development and characterisation of a panel of phosphatidylinositide 3-kinase–mammalian target of rapamycin inhibitor resistant lung cancer cell lines S Heavey, P Dowling, G Moore, MP Barr, N Kelly, SG Maher, S Cuffe, ... Scientific Reports 8 (1), 1652, 2018 | 11 | 2018 |
| Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer L Li, L Hobson, L Perry, B Clark, S Heavey, A Haider, A Sridhar, G Shaw, ... British journal of cancer 123 (6), 1024-1032, 2020 | 10 | 2020 |
| Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer S Luszczak, BS Simpson, U Stopka-Farooqui, VK Sathyadevan, ... Scientific reports 10 (1), 14380, 2020 | 10 | 2020 |
| Immunohistochemical biomarker validation in highly selective needle biopsy microarrays derived from mpMRI‐characterized prostates J Olivier, V Stavrinides, J Kay, A Freeman, H Pye, Z Ahmed, ... The Prostate 78 (16), 1229-1237, 2018 | 10 | 2018 |
Kathy GatelyTrinity College DublinVerified email at tcd.ie
